Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
82.99%
Operating Margin
-57.73%
Net Margin
-52.66%
Efficiency Metrics
Revenue per Expense Ratio
0.63
R&D as % of Revenue
0.66%
Earnings Quality
EBITDA Margin
32.35%
Income Tax Rate
-287,200,000,000.0%
EPS
-6.4900000000
Balance Sheet Analysis
Current Ratio
0.91
Cash Ratio
0.19
Working Capital
$-1.49B
Debt to Equity
0.76
Debt to Assets
33.47%
Equity Ratio
44.28%
Cash Flow Analysis
Operating Cash Flow Ratio
39.27%
Free Cash Flow Ratio
37.58%
CapEx to Revenue
1.69%
Dividends Paid
$5.06B
Stock Buybacks
$110.00M
Total Shareholder Returns
$5.17B
Cash Position Change
35.36%
Key Takeaways (2023 FY)
Revenue declined by 1.3451455433014%, indicating potential market challenges
Increased dividend payments by 5.53%
Increased R&D investment by 26.32%
Detailed Growth Metrics
Core Performance
Revenue
-1.35%
Net Income
-315.53%
EPS
-321.50%
Operating Income
-249.68%
Operational Efficiency
R&D Expenses
26.32%
SG&A Expenses
0.71%
Operating Cash Flow
3.08%
Free Cash Flow
3.88%
Balance Sheet Health
Assets
-22.68%
Debt
-7.90%
Book Value per Share
-29.08%
Inventory
-12.93%
Shareholder Returns
Dividends per Share
5.53%
Shares Outstanding
-1.41%
Long Term Trends
3Y Revenue/Share
7.36%
5Y Revenue/Share
12.99%
3Y Dividend/Share
9.32%
5Y Dividend/Share
19.32%